drugset / Trial / NCT00087776

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

NCT00087776

Phase 3 Terminated 393 enrolled American Regent, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.

Timeline

Start
2002-12-06
Primary completion
2007-10-27
Completion
2007-10-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dacarbazine Small molecule 1000 mg/m2 Intravenous
Subject PACLITAXEL DOCOSAHEXAENOIC ACID Small molecule 900 mg/m2 Intravenous

Indications